Supernus Pharmaceuticals Inc

NASDAQ:SUPN   1:17:41 PM EDT
29.34
+0.55 (+1.91%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.55B
Current PE11.95
Forward PE 12.07
2yr Forward PE 16.77
See more stats
Estimates Current Quarter
Revenue$145.85 Million
Adjusted EPS$0.53
See more estimates
10-Day MA$27.62
50-Day MA$23.43
200-Day MA$22.40
See more pivots

SUPERNUS PHARMACEUTICALS INC Stock, NASDAQ:SUPN

1550 E GUDE DR, ROCKVILLE, MD 20850
United States of America
Phone: 301-838-2500
Number of Employees: 448

Description

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.